PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
14.27%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.44%. Joel Greenblatt would see it as a clear outperformance relative to peers.
2.30%
D&A growth of 2.30% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
100.00%
Deferred tax growth of 100.00% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would see a difference that might matter for future cash flow if significant.
-60.58%
SBC declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
97.10%
Working capital of 97.10% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
100.06%
Inventory growth of 100.06% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question if expansions or new product lines require extra stock.
No Data
No Data available this quarter, please select a different quarter.
-18.36%
Other WC usage shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage if top-line is stable or growing.
-27.42%
Other non-cash items dropping yoy while Drug Manufacturers - Specialty & Generic median is -13.33%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
38.10%
CFO growth of 38.10% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
-133.43%
CapEx declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
-100.00%
Acquisition spending declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note reduced M&A risk if growth continues organically.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
93.88%
Growth of 93.88% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.
-14.40%
Reduced investing yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We reduce issuance yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.